Employing a slash-and-burn technique to streamline its pipeline, Vical Inc. said it is not completing its Phase III low-dose trial of Allovectin-7 in metastatic melanoma due to the improbability of it achieving desired endpoints, is closing a Phase II trial of Allovectin-7 for early stage head and neck cancer, and would no longer develop Leuvectin for prostate or kidney cancer. (BioWorld Today) Read More
